ArticleEcancermedicalscience2026
Prospective evaluation of locoregional control in oral cavity squamous cell carcinoma with lower or mid infratemporal fossa involvement treated with surgery and adjuvant concurrent chemoradiotherapy.
Article in Ecancermedicalscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Oral cavity squamous cell carcinoma (OCSCC) is the most prevalent malignancy of the head and neck malignancy in India. In locally advanced OCSCC, a combination of definitive surgery followed by postoperative radiotherapy (RT), with or without concurrent chemotherapy, offers superior oncologic outcomes compared to definitive chemoradiotherapy alone. The prognosis of T4b OCSCC with infratemporal fossa (ITF) involvement largely depended on the degree of invasion. Tumours confined to the lower or mid ITF tend to have relatively better outcomes than those with extensive or high-level involvement. This study prospectively evaluates the treatment outcomes in patients with OCSCC involving the lower or mid ITF who underwent curative surgical resection followed by adjuvant concurrent chemoradiotherapy (CCRT). Methods: This is a single-arm prospective interventional study between January 2021 and October 2022, which included 20 patients of clinically T4b OCSCC as per the American Joint Committee on Cancer (8th edition) with lower or mid ITF involvement. Patients with tumour invasion into the skull base, carotid artery, prevertebral fascia or pterygomaxillary fissure were excluded to maintain a uniform study cohort. All patients were treated with curative intent with surgery include ITF clearance followed by adjuvant CCRT. Primary endpoint was to evaluate loco-regional control (LRC) and secondary end point was to assess acute toxicities according to the Common Terminology Criteria for Adverse Events v5.0. Kaplan-Meier survival analysis was done for assessing disease free survival (DFS), overall survival (OS). Results: Median follow-up was 11.5 months (4-21 months). The median age was 39 years (range 32-67) with 95% males. Buccal mucosa was most common site with 19 patients (95%). All patients were clinically cT4b (Stage IV) stage involving low/mid ITF involvement with low ITF were 15(75%) and mid ITF patients were 5(25%) patients. All patients underwent definitive ITF clearance and received adjuvant CCRT with weekly concurrent cisplatin 35-40 mg/m Conclusion: Locally advanced OCSCC with low ITF involvement may benefit from tri-modality therapy of surgery with ITF clearance followed by adjuvant CCRT. The acute toxicity observed in study was within acceptable limits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.